Oral gene therapy for hypoparathyroidism: a rat model

Area of Science:

• Biotechnology
• Gene Therapy
• Pharmacology

Background:

• Parathyroid hormone (PTH) plays a crucial role in calcium regulation.
• Parathyroidectomy leads to significant disruptions in calcium homeostasis.
• Developing effective oral delivery systems for gene therapy remains a challenge.

Purpose of the Study:

• To investigate the efficacy of nonionic polymeric micelles for oral delivery of plasmid DNA encoding PTH (1-34).
• To evaluate the therapeutic potential of this oral gene therapy in parathyroidectomized rats.
• To assess the impact on serum calcium and PTH levels, as well as gene expression in target organs.

Main Methods:

• Plasmid DNA encoding human cytomegalovirus promoter (PCMV)-PTH(1-34) was prepared.
• Polymeric micelles (PEO-PPO-PEO) were formulated with the plasmid DNA.
• Parathyroidectomized rats received oral polymeric micelle formulations, with EDTA pretreatment, or served as controls.
• Serum calcium and PTH(1-34) levels were monitored weekly.
• Immunohistochemistry and RT-PCR were used to detect PTH(1-34) and its mRNA in various organs.

Main Results:

• Oral gene therapy with polymeric micelles significantly increased serum calcium and PTH(1-34) levels compared to control groups.
• Higher survival rates were observed in the study group compared to control groups.
• PTH(1-34) and its mRNA were detected in various organs of the study group, indicating successful gene expression.
• Relative mRNA densities were higher in the study group than in the drinking water control group.

Conclusions:

• Oral gene therapy using nonionic polymeric micelles is a viable strategy for delivering the PTH(1-34) gene.
• This approach can effectively maintain serum calcium and PTH levels in parathyroidectomized rats.
• Polymeric micelle-based oral gene therapy holds promise for treating conditions related to parathyroid hormone deficiency.